Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - tablets - candesartan cilexetil 16 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - hepatitis b immunoglobulin - solution for injection - hepatitis b immunoglobulin 312 iu/ml - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b recurrence following liver transplantation : hepagam b is indicated for the prevetion of hepatitis b recurrence following liver transplantation in hbsag-positive liver transplant patients. hepagam b should be administered intravenously for this indication.postexposure prophylaxis : hepagam b is indicated for the treatment of acute exposure to blood containing hbsag perinatal exposure of infants born to hbsag-positive mothers sexual exposure to hbsag-positive persons and household exposure to persons with acute hbv infection in the following settings: acute exposure to blood containing hbsag following either parenteral exposure (needlestick bite sharps) direct mucous membrane contact (accidental splash) or oral ingestion (pipetting accident) involving hbsag - positive materials such as blood plasma or serum. perinatal exposure of infants born to hbsag-positive mothers infants born to mothers positive for hbsag with or without hbeag. perinatal exposure of infants born to hbsag-positive persons sexual partners of hbsag-positive persons. household exposure to persons with acute hbv infection infants less than 12 months old whose mother or primary caregiver is positive for hbsag. other household contacts with an identifiable blood exposure to the index patient. hepagam b is indicated for intramuscular use only for these post-exposure prophylaxis indications.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg / 1 ml - enoxaparin - crusia is indicated in adults for:•prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.•prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.•treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe ikely to require thrombolytic therapy or surgery. prevention of thrombus formation in extra corporeal circulation during haemodialysis.•acute coronary syndrome:-treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid.-treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - doxylamine succinate; pyridoxine (vit b6) hydrochloride - tablets extended release - doxylamine succinate 20 mg; pyridoxine (vit b6) hydrochloride 20 mg - doxylamine - bonjesta is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.limitations of usebonjesta has not been studied in women with hyperemesis gravidarum.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 1000 mg/vial - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 200 mg/vial - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 500 mg/vial - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 200 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1000 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Izrael - engleski - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locallyadvanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreaticcancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locallyrecurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelialovarian carcinoma whom have relapsed at least six months after platinum - based therapy.